Combination Therapy for Cancer Using HSP27 Inhibitor and EGFR Tyrosine Kinase Inhibitors or Anti-Folates,申请号US201314372972-传众专利搜索

Combination Therapy for Cancer Using HSP27 Inhibitor and EGFR Tyrosine Kinase Inhibitors or Anti-Folates

申请公布号：US2015050285(A1)

申请号：US201314372972

申请日期：2013.02.01

申请公布日期：2015.02.19

申请人：

The University of British Columbia

发明人：Gleave Martin E.;Zoubeidi Amina;Kumano Masafumi

分类号：A61K39/395;A61K31/5377;A61K31/7088;A61K31/517

主分类号：A61K39/395

地址：Vancouver CA

摘要：Combination therapy for cancer makes use of HSP27 inhibitors and EGFR tyrosine kinase inhibitors or antifolates.

主权项：1. A method for treating cancer in an individual, comprising the steps of administering to the individual a therapeutically effective amount of a first active agent which is an inhibitor of Hsp27 activity, and administering to the individual therapeutically effective amount of a second active agent which is an inhibitor of EGFR tyrosine kinase activity.